<DOC>
	<DOCNO>NCT00239486</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety different dos pramipexole ( Sifrol ) subjective objective symptom idiopathic Restless Legs Syndrome ( RLS ) also determine optimal dose pramipexole patient RLS polysomnography evaluation clinical improvement .</brief_summary>
	<brief_title>Dose Finding Study Pramipexole ( Sifrol ) Patients With Idiopathic Restless Legs Syndrome ( RLS )</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Psychomotor Agitation</mesh_term>
	<mesh_term>Restless Legs Syndrome</mesh_term>
	<mesh_term>Pramipexole</mesh_term>
	<criteria>1 . Male female 1880 year 2 . Confident diagnosis RLS accord International RLS Study Group criteria 3 . RLS rating scale severity score &gt; 15 4 . PLM ( time bed ) index least 5 per hour 5 . Weekly presence RLS symptom within last three month 6 . Written Informed consent 1 . Women childbearing potential , use adequate protection barrier protection , intrauterine device , hormonal ( oral subcutaneous ) contraception 2 . Postmenopausal woman less 6 month last menses , surgically sterilise , oophorectomised hysterectomised less 3 month operation use adequate protection 3 . Women neither use adequate protection postmenopausal partner sterilise least 6 month post operation use condom 4 . Any woman negative serum pregnancy test screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2013</verification_date>
</DOC>